Fluid Resuscitation in Early Septic Shock (PRECISE)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Severe infection in the intensive care unit is common accounting for about 10% of admissions and has a death rate of approximately 40-50%. It is almost always associated with significant reductions in blood pressure. Administration of fluid often in large volumes is essential to normalize blood pressure and prevent failure of organs and death. Two common classes of fluid solutions are crystalloid fluids (salt based, normal saline) and colloid fluids (protein based, albumin). Due to its properties, the albumin fluid may remain in the vascular space better than the normal saline solution. Hence, there may be faster attainment of normal blood pressure as well as a reduction in failed organs and death. Preliminary clinical trial data suggests a potential for benefit with albumin in this setting but these findings require confirmation in a large clinical trial.
There are few data to explain how albumin may exert its protective effects and lead to better outcomes for patients with severe infections. We will conduct a clinical study that will examine potential biological mechanisms for albumin's protective effects in 50 patients across 6 Canadian academic hospitals. We will also examine our ability to successfully recruit patients into this trial.
This study will provide information that will help to understand the biological mechanisms of albumin in severe infection. The information gained will guide the investigative team for future fluid related mechanistic questions. The study will also provide essential information that will aid in the design and conduct of the future large clinical trial that will examine death as its primary outcome.
| Condition | Intervention | Phase |
|---|---|---|
|
Septic Shock Sepsis Severe Sepsis |
Drug: 5% albumin Drug: Normal Saline |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacodynamics Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Five Percent Albumin Versus Normal Saline as Fluid Resuscitation Strategies for the Management of Early Suspected Septic Shock |
- Comparison of thrombin generation and protein C and APC levels [ Time Frame: Thrombin generation at 72 hours and protein C and APC levels at 7 days after randomization ] [ Designated as safety issue: No ]
- Comparison of blood and urine pro and anti-inflammatory cytokine and chemokine levels.Clinical outcomes include mortality, length of stay,organ failure, and organ support measures. [ Time Frame: Inflammatory markers measured first 7 days of care. Mortality in ICU/hospital/30 days. Length of stay ICU/hospital. Organ failure first 7 days of care. ] [ Designated as safety issue: No ]
| Enrollment: | 47 |
| Study Start Date: | February 2009 |
| Study Completion Date: | February 2010 |
| Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
5% albumin
|
Drug: 5% albumin
5% albumin for the first 7 days of care in the ICU
Other Name: colloid fluid
|
|
2
Normal saline
|
Drug: Normal Saline
Normal Saline for the first 7 days of care in the ICU
Other Name: crystalloid fluid
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Eligible patients will meet the following 2 inclusion criteria.
- Refractory Hypotension: The patient has received at least 1 litre of normal saline or ringers lactate crystalloid fluid for hypotension (defined as a systolic blood pressure less than 90 mm Hg, or a systolic blood pressure more than 40 mm Hg below baseline, or a mean arterial blood pressure less than 65 mm Hg) within 8 hours of the first hypotensive event and has refractory hypotension defined by: a) Presence of hypotension OR b) Initiation of a vasopressor agent(s).
- Two or more criteria for the systemic inflammatory response syndrome (SIRS): i) heart rate greater than 90 beats per minute; ii) respiratory rate greater than 20 breathes per minute, or a PaC02 less than 32 mm Hg, or mechanically ventilated; iii) temperature greater than 38 or less than 36 degrees Celsius; iv) or a white blood cell count greater than 12,000 x 109/L or less than 4,000 x 109/L, or more than 10% bands on the differential.
Exclusion Criteria:
- Clinically apparent other forms of shock including cardiogenic, obstructive (massive pulmonary embolism, cardiac tamponade, tension pneumothorax) or hemorrhagic shock
- Previous admission to ICU with severe sepsis or septic shock during the index hospitalization
- More than 250 mls of colloid fluid (Pentaspan, Voluven, Hextend, or albumin) from the first episode of hypotension
- A known previous severe reaction to albumin
- Burns
- Known cirrhosis
- Traumatic brain injury
- Religious objection to albumin use
- Less than 18 years of age
- Pregnant
- Family or patient not committed to aggressive care
- Currently enrolled in another related interventional study.
Contacts and Locations| Canada, Alberta | |
| University of Alberta Hospital | |
| Edmonton, Alberta, Canada, T6G 2B7 | |
| Canada, Manitoba | |
| Winnipeg Health Sciences Center | |
| Winnipeg, Manitoba, Canada, R3P 0X1 | |
| Canada, Nova Scotia | |
| Halifax Capital Health Center | |
| Halifax, Nova Scotia, Canada, B3H 2Y9 | |
| Canada, Ontario | |
| Hamilton General Hospital | |
| Hamilton, Ontario, Canada, L8N 3Z5 | |
| Ottawa Hospital Research Institute | |
| Ottawa, Ontario, Canada, K1H 8L6 | |
| Canada, Quebec | |
| Hôpital de l'Enfant-Jésus | |
| Quebec City, Quebec, Canada, G1J 1Z4 | |
| Principal Investigator: | Lauralyn A McIntyre, MD | Ottawa Hospital Research Institute |
| Principal Investigator: | Alan Tinmouth, MD | Ottawa Hospital Research Institute |
| Principal Investigator: | Alison Fox Robichaud, MD | Hamilton Health Sciences Corporation |
More Information
No publications provided
| Responsible Party: | Lauralyn McIntyre MD, FRCPC, MHSc, Ottawa Hospital Research Institute |
| ClinicalTrials.gov Identifier: | NCT00819416 History of Changes |
| Other Study ID Numbers: | 2008640 |
| Study First Received: | January 8, 2009 |
| Last Updated: | April 13, 2010 |
| Health Authority: | Canada: Ethics Review Committee |
Keywords provided by Ottawa Hospital Research Institute:
|
randomized controlled trial clinical trial |
Additional relevant MeSH terms:
|
Sepsis Toxemia Shock Shock, Septic |
Infection Systemic Inflammatory Response Syndrome Inflammation Pathologic Processes |
ClinicalTrials.gov processed this record on May 23, 2013